Merck Serono S. A.

Ares Trading S.a.

Merck Patent Gmbh

Yeda Research and Develpment & Co. Ltd

Institut National De La Sante Et De La Recherche Medicale

Inserm (institut National De La Sante Et De La Recherche Medicale)

Yolande Chvatchko

Michael John Scott Saunders

Christine Power

Olivier Leger

Joost Alexander Kolkman

Richard Fagan

Christopher Benjamin Phelps

Heidi Rommelaere

Ann Union

Ursula Boschert

Alain Vicari

Laurent Chevalet

Denis Bruniquel

Amanda E I Proudfoot

Charles A Dinarello

Menachem Rubinstein

Daniela Novick

Alain Tedgui

Ziad Mallat

Soo Hyun Kim

Christine Plater-Zyberk

Andrew Robert Davids

Marie Kosco-Vilbois

Jean-Pierre Gotteland

Pascale Gaillard

Philippe Langella

Soo-Hyun Kim

Leonid Reznikov

Jean-Marc Chatel

Laurence Goffin

Camille Aubry

Benjamin Pomerantz

Richard James Mitter

Luis Bermudez-Humaran

Anne Corbaz

Yves Sagot

Simone Favre-Zimmerli

Michael John Saunders

Alden Harken

Amanda EI Proudfoot

Santer Van Deventer

The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same

The present invention relates to recombinantbacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics

Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same

The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.

Use of IL-18BP for treatment of peripheral vascular diseases

Method of treating peripheral vascular diseases using IL-18 inhibitors

The invention relates to the use of an IL18-BP isoform that does not bind to IL18, or of an agonist thereof, for treatment or prevention of a neurological and/or inflammatory disease. Preferred isoforms for use in the frame of the invention include IL-18BPb and IL-18BPd.

Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases

The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.

Use of soluble CD164 in inflammatory and/or autoimmune disorders

This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.

Method of treatment comprising administration of a cytokine antagonist molecule

The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and/or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring/wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction. 

Benzazole derivatives for the treatment of scleroderma

Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding them. DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided. Therapeutic uses of IL-18 binding proteins and further inhibitors of IL-18 are also provided according to the invention.

Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins

This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.

Cytokine antagonist molecules

This invention relates to proteins termed INSP005and INSP005, herein identified as secreted proteins, in particular members of the metalloprotease family and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease.

Metalloprotease proteins

Interleukin-18 binding proteins, their preparation and use

Growing community of inventors

Confignon, Switzerland

Yolande Chvatchko